Insider Buying: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Purchases 130,000 Shares of Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) Director Sheila Gujrathi purchased 130,000 shares of the firm’s stock in a transaction on Monday, December 23rd. The shares were acquired at an average price of $2.31 per share, with a total value of $300,300.00. Following the purchase, the director now directly owns 130,000 shares in the company, valued at $300,300. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock traded up $0.06 during mid-day trading on Thursday, reaching $2.33. The company’s stock had a trading volume of 1,299,879 shares, compared to its average volume of 2,038,414. The firm’s fifty day moving average price is $2.29 and its two-hundred day moving average price is $2.33. Ventyx Biosciences, Inc. has a 12-month low of $1.67 and a 12-month high of $11.48. The company has a market capitalization of $164.76 million, a P/E ratio of -0.99 and a beta of 0.48.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on VTYX. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.00.

Institutional Trading of Ventyx Biosciences

Several institutional investors and hedge funds have recently modified their holdings of VTYX. SG Americas Securities LLC purchased a new stake in Ventyx Biosciences during the second quarter valued at about $32,000. Bank of New York Mellon Corp lifted its position in Ventyx Biosciences by 58.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock worth $533,000 after buying an additional 84,984 shares during the last quarter. Rhumbline Advisers boosted its stake in Ventyx Biosciences by 38.0% in the second quarter. Rhumbline Advisers now owns 90,331 shares of the company’s stock worth $209,000 after buying an additional 24,885 shares in the last quarter. Acadian Asset Management LLC bought a new position in Ventyx Biosciences during the second quarter valued at approximately $608,000. Finally, American Century Companies Inc. purchased a new position in shares of Ventyx Biosciences during the second quarter worth approximately $60,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.